Marker Therapeutics, Inc. · NASDAQ:MRKR
Marker Therapeutics — Investor Presentation (August 2025)
20 slides from Marker Therapeutics's investor presentation, Aug 26, 2025
Slide 1: Marker Therapeutics Corporate Presentation
MARKER THERAPEUTICS CORPORATE PRESENTATION August 2025 NASDAQ: MRKR
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained herein are forward - looking statements within the meaning of Section 21 E of the Securities Exchange Act of 1934 , as amended, and Section 27 A of the Securities Act of 1933 , as amended, that involve risks and uncertainties . All statements o
Slide 3: Marker Therapeutics – Value Proposition
3 MAR - T Cell Platform MAR - T (Multi - Antigen Recognizing T cell, formerly known as multiTAA) technology was developed at Baylor College of Medicine and, we believe, offers key therapeutic and manufacturing advantages over traditional T cell therapies Attractive Safety Profile MAR - T cells are n
Slide 4: MAR-T Technology
MAR - T Technology 4
Slide 5: Mechanism of Action of MAR-T Cells
5 • MAR - T cells target up to 6 antigens 1, 2 for a more potent, durable anti - tumor response. • MAR - T cells lack genetic modification; Natural T cells expanded ex vivo pose no mutagenesis risk. • MAR - Ts intend to address challenges faced by Bispecific Antibodies, CAR - T and TCR approaches. •
Slide 6: MAR-T Cells are Generated in a Simple Manufacturing Process
• No genetic engineering • Natural T cell expansion • Uninterrupted cell expansion • Reproducible process • Cost - effective process PBMC, peripheral blood mononuclear cells. 6 MAR - T Cells are Generated in a Simple Manufacturing Process
Slide 7: MAR-T Pipeline for Hematologic Malignancies and Solid Tumors
MAR - T Pipeline for Hematologic Malignancies and Solid Tumors 7 PHASE 2 PHASE 1 IND PRECLINICAL PROGRAM / INDICATION HEMATOLOGIC MALIGNANCIES MT - 601 1 (APOLLO) Lymphoma – Autologous MT - 401 - OTS 2 AML – Allogenic Off - the - Shelf (OTS) SOLID TUMORS MT - 601 1 Pancreatic Cancer – Autologous AML
Slide 8: MT-601 APOLLO Study
MT - 601 – APOLLO STUDY MAR - Ts targeting 6 tumor antigens for patients with lymphoma who relapsed after anti - CD 19 CAR - T cells or where CAR - T cell therapy is not an option 8
Slide 9: APOLLO Study Utilizes an Optimized MAR-T Cell Product
APOLLO Study Utilizes an Optimized MAR - T Cell Product 9 MARKER’S MT - 601 STUDY (APOLLO) BAYLOR STUDY (1) • MAR - T cell product targeted 5 tumor antigens • Demonstrated durable responses for up to 5 years without CRS or ICANS • Cell Dose: 10x10 6 – 40x10 6 • Manufacturing Process: • Average Poten
Slide 10: Marker APOLLO Clinical Trial Design
Marker MT - 601 APOLLO Clinical Trial Design Lymphoma Patient 10 MT - 601 Dose Escalation 100 - 400 x 10 6 cells N=24 STUDY DESIGN Enroll different histopathologies (e.g. DLBCL, FL, MZL, MCL, HL) Histopathology - specific (DLBCL – CAR - T and/or Bispecific relapse) DLBCL, Diffuse Large B Cell Lympho
Slide 11: Early Objective Responses in Participants with Non-Hodgkin Lymphoma
MT - 601 Shows Early Objective Responses in Participants with Non - Hodgkin Lymphoma (NHL) 20 0 Best Response 40 60 80 100 Percentage (%) Complete Response Partial Response Progressive Disease ORR=66% CRR=50% N = 12 Study participant diagnosed with LBCL had 10 prior treatment lines (incl . bispecifi
Slide 12: Patients Treated in Phase 1 APOLLO Trial – Non-Hodgkin Lymphoma
0 3 6 18 007 - 601 007 - 603 007 - 604 009 - 603 008 - 601 009 - 601 010 - 601 010 - 602 004 - 602 007 - 602 001 - 602 005 - 601 Patients Treated 12 Patients Treated in Phase 1 APOLLO Trial – Non - Hodgkin Lymphoma 9 12 15 Months Follow - Up MT - 601 infusion ǂ Complete Response Partial Response ǂ C
Slide 13: Study Participants with NHL show Early Objective Responses
13 Study Participants with NHL show Early Objective Responses Complete Response Partial Response CR, Complete Response; PR, Partial Response; PD, Progressive Disease; LD, Lymphodepletion; FL, Follicular Lymphoma; LBCL, Large B Cell Lymphoma; MZL , Marginal Zone Lymphoma; MCL, Mantle Cell Lymphoma. B
Slide 14: Study Participants with HL show Early Objective Responses
14 Study Participants with HL show Early Objective Responses HL, Hodgkin’s Lymphoma. (1) Patient scan provided by Dr. Haitham Abdelhakim (University of Kansas). 40 Percentage (%) 20 0 Best Response Progressive Disease Partial Response Complete Response Response Rates N = 9 100 80 60 ORR=78% CRR=11%
Slide 15: Appears Safe and Well Tolerated
MT - 601 Appears Safe and Well Tolerated No Dose Limiting Toxicities (DLTs) reported (doses tested ranged from 100x10 6 to 400x10 6 cells) 2 Grade 1 CRS events reported (fever; no treatment required) No ICANS reported Long term toxicities currently being assessed CRS, Cytokine Release Syndrome; ICAN
Slide 16: Relapsed Lymphoma is a Large, Growing Market Opportunity
16 Relapsed Lymphoma is a Large, Growing Market Opportunity • Autologous CD 19 CAR - Ts have become a standard of care in R/R NHL, generating global revenues of $ 3 . 1 B in 2024 ( 26 % y/y growth) • CAR - Ts are expected to show sustained growth based on label/geographic expansion and continued low
Slide 17: Future Developments
Future Developments 17
Slide 18: MT-401-OTS & MT-401 – Advancing Allogeneic and Solid Tumor Programs
MT - 401 - OTS & MT - 601 – Advancing Allogeneic and Solid Tumor Programs 18 MT - 401 Off - the - Shelf MT - 601 in Pancreatic Cancer • Manufactured from healthy donors ; Marker has cellular inventory with plans to expand • PoC studies completed with data supporting clinical benefits of technology •
Slide 19: Key Takeaways
Key Takeaways 19 In contrast to single antigen - targeting T cell therapies, MAR - Ts target multiple epitopes within up to 6 tumor - specific antigens, thereby reducing the possibility of tumor escape MAR - Ts do not require genetic engineering APOLLO study highlights: • MT - 601 was well - tolerat
Slide 20: Thank You
THANK YOU 20
Marker Therapeutics — Investor Presentation (August 2025) on 6ix